Fidelity Investments
ANTX icon

Fidelity Investments’s AN2 Therapeutics ANTX Stock Holding History

Fidelity Investments’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,200
Closed -$1.37K – 5419
2025
Q4 		$1.37K Buy
1,200
+200
+20% +$234 ﹤0.01% 5066
2025
Q3 		$1.27K Buy
+1,000
New +$1.14K ﹤0.01% 4993
2024
Q4 		– Sell
-300
Closed -$321 – 5533
2024
Q3 		$321 Buy
+300
New +$521 ﹤0.01% 5008
2024
Q1 		– Sell
-670
Closed -$13.7K – 5348
2023
Q4 		$13.7K Hold
670
– – ﹤0.01% 4126
2023
Q3 		$10.8K Hold
670
– – ﹤0.01% 4089
2023
Q2 		$5.7K Buy
670
+363
+118% +$2.61K ﹤0.01% 4324
2023
Q1 		$3.03K Buy
307
+56
+22% +$623 ﹤0.01% 4523
2022
Q4 		$2.39K Buy
251
+235
+1,469% +$3.15K ﹤0.01% 4464
2022
Q3 		$0 Buy
+16
New +$187 ﹤0.01% 4813

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Fidelity Investments's ANTX Position: Q1 2026 in Review

Fidelity Investments sold out of AN2 Therapeutics (ANTX) in Q1 2026, closing a stake of 1,200 shares — an estimated $1.37K sold.

Fidelity Investments first reported a position in ANTX in Q3 2022 and held it in 9 quarters. The position peaked at $13.7K in Q4 2023. 52 funds tracked by Wall St. Rank hold ANTX as of Q1 2026.

  • Fidelity Investments reported no remaining AN2 Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Fidelity Investments sold 1,200 AN2 Therapeutics shares in Q1 2026, an estimated $1.37K.
  • Fidelity Investments first reported a position in AN2 Therapeutics in Q3 2022 and held it in 9 quarters.
  • Fidelity Investments's AN2 Therapeutics position peaked at $13.7K in Q4 2023.
  • 52 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.